# Nitin T Supekar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5749016/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 22 papers | 1,196 citations | 516710 16 h-index | 677142 22 g-index |
| 25 all docs | 25 docs citations | 25 times ranked | 2412 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2. Glycobiology, 2021, 31, 410-424. | 2.5 | 125 |
| 2 | Structural basis of Blastomyces Endoglucanase-2 adjuvancy in anti-fungal and -viral immunity. PLoS Pathogens, 2021, 17, e1009324. | 4.7 | 7 |
| 3 | Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein. Glycobiology, 2021, 31, 1080-1092. | 2.5 | 31 |
| 4 | OUP accepted manuscript. Glycobiology, 2021, , . | 2.5 | 2 |
| 5 | Regulating colonic dendritic cells by commensal glycosylated large surface layer protein A to sustain gut homeostasis against pathogenic inflammation. Mucosal Immunology, 2020, 13, 34-46. | 6.0 | 15 |
| 6 | Role of glycosylation on the ensemble of conformations in the MUC1 immunodominant epitope. Journal of Peptide Science, 2020, 26, e3229. | 1.4 | 3 |
| 7 | Mass Spectrometric Method for the Unambiguous Profiling of Cellular Dynamic Glycosylation. ACS Chemical Biology, 2020, 15, 2692-2701. | 3.4 | 19 |
| 8 | Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Glycobiology, 2020, 30, 981-988. | 2.5 | 420 |
| 9 | Simplifying Glycan Profiling through a High-Throughput Micropermethylation Strategy. SLAS Technology, 2020, 25, 367-379. | 1.9 | 12 |
| 10 | Sequence-Specific Mucins for Glycocalyx Engineering. ACS Synthetic Biology, 2019, 8, 2315-2326. | 3.8 | 17 |
| 11 | Glycosylation Is Vital for Industrial Performance of Hyperactive Cellulases. ACS Sustainable Chemistry and Engineering, 2019, 7, 4792-4800. | 6.7 | 19 |
| 12 | High-Throughput Automated Micro-permethylation for Glycan Structure Analysis. Analytical Chemistry, 2019, 91, 1237-1240. | 6.5 | 23 |
| 13 | Identification of a secondary binding site in human macrophage galactose-type lectin by microarray studies: Implications for the molecular recognition of its ligands. Journal of Biological Chemistry, 2019, 294, 1300-1311. | 3.4 | 31 |
| 14 | Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. ChemBioChem, 2018, 19, 121-125. | 2.6 | 14 |
| 15 | Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen. Glycobiology, 2017, 27, 677-687. | 2.5 | 45 |
| 16 | Tool for Rapid Analysis of Glycopeptide by Permethylation via One-Pot Site Mapping and Glycan Analysis. Analytical Chemistry, 2017, 89, 10734-10743. | 6.5 | 40 |
| 17 | Distinct roles of N- and O-glycans in cellulase activity and stability. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13667-13672. | 7.1 | 76 |
| 18 | MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice. PLoS ONE, 2016, 11, e0145920. | 2.5 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Synthetic Receptors for the Highâ€Affinity Recognition of Oâ€GlcNAc Derivatives. Angewandte Chemie - International Edition, 2016, 55, 3387-3392. | 13.8 | 86 |
| 20 | Mucin architecture behind the immune response: design, evaluation and conformational analysis of an antitumor vaccine derived from an unnatural MUC1 fragment. Chemical Science, 2016, 7, 2294-2301. | 7.4 | 35 |
| 21 | Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide. Chemical Communications, 2015, 51, 10214-10217. | 4.1 | 51 |
| 22 | Immune and Anticancer Responses Elicited by Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccines Modified by a TLR2 or TLR9 Agonist. ChemBioChem, 2014, 15, 1508-1513. | 2.6 | 60 |